264 related articles for article (PubMed ID: 28628042)
1. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.
Chang AY; Dao T; Gejman RS; Jarvis CA; Scott A; Dubrovsky L; Mathias MD; Korontsvit T; Zakhaleva V; Curcio M; Hendrickson RC; Liu C; Scheinberg DA
J Clin Invest; 2017 Jun; 127(7):2705-2718. PubMed ID: 28628042
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic targeting of PRAME with mTCRCAR T cells in acute myeloid leukemia.
Kirkey DC; Loeb AM; Castro S; McKay CN; Perkins L; Pardo L; Leonti AR; Tang TT; Loken MR; Brodersen LE; Loeb KR; Scheinberg DA; Le Q; Meshinchi S
Blood Adv; 2023 Apr; 7(7):1178-1189. PubMed ID: 35984639
[TBL] [Abstract][Full Text] [Related]
3. Development of a T-cell receptor mimic antibody targeting a novel Wilms tumor 1-derived peptide and analysis of its specificity.
Kurosawa N; Midorikawa A; Ida K; Fudaba YW; Isobe M
Cancer Sci; 2020 Oct; 111(10):3516-3526. PubMed ID: 32770595
[TBL] [Abstract][Full Text] [Related]
4. Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma.
Orlando D; Miele E; De Angelis B; Guercio M; Boffa I; Sinibaldi M; Po A; Caruana I; Abballe L; Carai A; Caruso S; Camera A; Moseley A; Hagedoorn RS; Heemskerk MHM; Giangaspero F; Mastronuzzi A; Ferretti E; Locatelli F; Quintarelli C
Cancer Res; 2018 Jun; 78(12):3337-3349. PubMed ID: 29615432
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia.
Quintarelli C; Dotti G; De Angelis B; Hoyos V; Mims M; Luciano L; Heslop HE; Rooney CM; Pane F; Savoldo B
Blood; 2008 Sep; 112(5):1876-85. PubMed ID: 18591381
[TBL] [Abstract][Full Text] [Related]
6. TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models.
Verma B; Neethling FA; Caseltine S; Fabrizio G; Largo S; Duty JA; Tabaczewski P; Weidanz JA
J Immunol; 2010 Feb; 184(4):2156-65. PubMed ID: 20065111
[TBL] [Abstract][Full Text] [Related]
7. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
[TBL] [Abstract][Full Text] [Related]
8. High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.
Quintarelli C; Dotti G; Hasan ST; De Angelis B; Hoyos V; Errichiello S; Mims M; Luciano L; Shafer J; Leen AM; Heslop HE; Rooney CM; Pane F; Brenner MK; Savoldo B
Blood; 2011 Mar; 117(12):3353-62. PubMed ID: 21278353
[TBL] [Abstract][Full Text] [Related]
9. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death.
Wittman VP; Woodburn D; Nguyen T; Neethling FA; Wright S; Weidanz JA
J Immunol; 2006 Sep; 177(6):4187-95. PubMed ID: 16951384
[TBL] [Abstract][Full Text] [Related]
10. Assessing vaccine potency using TCRmimic antibodies.
Neethling FA; Ramakrishna V; Keler T; Buchli R; Woodburn T; Weidanz JA
Vaccine; 2008 Jun; 26(25):3092-102. PubMed ID: 18353510
[TBL] [Abstract][Full Text] [Related]
11. Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library.
Chames P; Hufton SE; Coulie PG; Uchanska-Ziegler B; Hoogenboom HR
Proc Natl Acad Sci U S A; 2000 Jul; 97(14):7969-74. PubMed ID: 10884427
[TBL] [Abstract][Full Text] [Related]
12. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
[TBL] [Abstract][Full Text] [Related]
13. Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.
Zhao Q; Ahmed M; Tassev DV; Hasan A; Kuo TY; Guo HF; O'Reilly RJ; Cheung NK
Leukemia; 2015 Nov; 29(11):2238-47. PubMed ID: 25987253
[TBL] [Abstract][Full Text] [Related]
14. PRAME peptide-specific CD8
Matko S; Manderla J; Bonsack M; Schmitz M; Bornhauser M; Tonn T; Odendahl M
Eur J Immunol; 2018 Aug; 48(8):1400-1411. PubMed ID: 29738081
[TBL] [Abstract][Full Text] [Related]
15. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors.
McCormack E; Adams KJ; Hassan NJ; Kotian A; Lissin NM; Sami M; Mujić M; Osdal T; Gjertsen BT; Baker D; Powlesland AS; Aleksic M; Vuidepot A; Morteau O; Sutton DH; June CH; Kalos M; Ashfield R; Jakobsen BK
Cancer Immunol Immunother; 2013 Apr; 62(4):773-85. PubMed ID: 23263452
[TBL] [Abstract][Full Text] [Related]
16. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.
Cameron BJ; Gerry AB; Dukes J; Harper JV; Kannan V; Bianchi FC; Grand F; Brewer JE; Gupta M; Plesa G; Bossi G; Vuidepot A; Powlesland AS; Legg A; Adams KJ; Bennett AD; Pumphrey NJ; Williams DD; Binder-Scholl G; Kulikovskaya I; Levine BL; Riley JL; Varela-Rohena A; Stadtmauer EA; Rapoport AP; Linette GP; June CH; Hassan NJ; Kalos M; Jakobsen BK
Sci Transl Med; 2013 Aug; 5(197):197ra103. PubMed ID: 23926201
[TBL] [Abstract][Full Text] [Related]
17. Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1
Shenderov E; Kandasamy M; Gileadi U; Chen J; Shepherd D; Gibbs J; Prota G; Silk JD; Yewdell JW; Cerundolo V
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088742
[TBL] [Abstract][Full Text] [Related]
18. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy.
Griffioen M; Kessler JH; Borghi M; van Soest RA; van der Minne CE; Nouta J; van der Burg SH; Medema JP; Schrier PI; Falkenburg JH; Osanto S; Melief CJ
Clin Cancer Res; 2006 May; 12(10):3130-6. PubMed ID: 16707612
[TBL] [Abstract][Full Text] [Related]
19. Efficient identification of novel HLA-A(*)0201-presented cytotoxic T lymphocyte epitopes in the widely expressed tumor antigen PRAME by proteasome-mediated digestion analysis.
Kessler JH; Beekman NJ; Bres-Vloemans SA; Verdijk P; van Veelen PA; Kloosterman-Joosten AM; Vissers DC; ten Bosch GJ; Kester MG; Sijts A; Wouter Drijfhout J; Ossendorp F; Offringa R; Melief CJ
J Exp Med; 2001 Jan; 193(1):73-88. PubMed ID: 11136822
[TBL] [Abstract][Full Text] [Related]
20. The Antitumor Activity of TCR-Mimic Antibody-Drug Conjugates (TCRm-ADCs) Targeting the Intracellular Wilms Tumor 1 (WT1) Oncoprotein.
Shen Y; Li YM; Zhou JJ; Zhou Z; Xu YC; Zhao WB; Chen SQ
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31408937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]